Maypro introduces highly bio-available quercetin to U.S.

Maypro-introduces-highly-bio-available-quercetin-to-U.S.jpg
EubioQuercetin combines quercetin derived from the Japanese pagoda tree (pictured) with a unique non-digestible oligosaccharide prebiotic, rutinose. Image © apugach / Getty Images

New York-based Maypro has announced a partnership with Japan-based Alps Pharmaceutical to bring EubioQuercetin, a highly absorbable formulation of quercetin, to the U.S. market.

The ingredient is claimed to be 6,500 times more water soluble than conventional, commercially available quercetin.

“Manufacturers that include EubioQuercetin in their formulations can formulate with a low daily dose of 125 mg for natural anti-aging efficacy compared to conventional quercetin, which requires manufacturers to include quercetin at doses as high as 1,000 mg,” said Isabel Elias-Castro, President of the Maypro Global Nutrition Group.

Quercetin

Quercetin (3,5,7,3′,4′-pentahydroxyflavone) is a polyphenolic flavonoid found naturally in common foods like onions and apples.  It has potent antioxidant and anti-inflammatory activity, with reported benefits for cognitive health and mood, blood pressure, cardiovascular health and sports nutrition, among many other indications.

According to futuremarketinsights.com, the global quercetin revenue was $1.3 billion in 2022, and the market it expected to grow at a compound annual growth rate (CAGR) of 12.4% between 2022 and 2032 to reach almost $4 billion by 2032. The US accounts for approximately 49% of the global market.

Conventional quercetin ingredients are said to be poorly absorbed, and manufacturers are therefore required to include quercetin at doses as high as 1,000 mg, according to Maypro.

While some other ingredient suppliers use a phytosome delivery form or enzymatically treat quercetin to boost bioavailability, EubioQuercetin combines quercetin derived from the Japanese pagoda tree (Sophora japonica) with a unique non-digestible oligosaccharide prebiotic, rutinose.  The result is a proprietary quercetin that is effective at a low daily dose of 125 mg in these same formulations, Maypro shared in a press release.

“We’re happy to partner with Maypro on the North American introduction of our EubioQuercetin ingredient, which we refer to as ‘The World’s First Evolved Prebiotic Quercetin,’” said Osamu Ushimaru, president of Alps Pharmaceuticals.

“Without artificial modification, we devised a method to increase the solubility and absorption in the body while maintaining the delivery of Quercetin-Rutinoside to the colon, thereby achieving the combined effects of rutinose and quercetin,” he added.